Literature DB >> 30245398

A cardiac glycoside HTF-1 isolated from Helleborus thibetanus Franch displays potent in vitro anti-cancer activity via caspase-9, MAPK and PI3K-Akt-mTOR pathways.

Long Ma1, Yuanyuan Meng2, Chunhao Tu2, Xiuqi Cao2, Haiyue Wang2, Yuyin Li3, Shuli Man3, Jin Zhou2, Miao Li2, Zhenxing Liu3, Yanfang Su4.   

Abstract

Experiments have been undertaken and for the first time, we have identified that a new cardiac glycoside (CG) isolated from Helleborus thibetanus Franch. a plant endemic to China, bears potent anti-cancer activity. We have named it as HTF-1. By using in vitro cell models, we have found that HTF-1 induces apoptosis against several types of cancer cells in a concentration- and time-dependent manner. It is able to inhibit cancer cell in proliferation, migration and invasion. HTF-1 causes S cell cycle arrest. Further-on, we have identified that HTF-1 triggers caspase-9 dependent apoptosis pathway and double strand DNA breaks (DSBs). Additionally, HTF-1 activates JNK, but suppresses ERK and PI3K-Akt-mTOR pathways. Collectively, the above-mentioned mechanisms contribute to the anti-cancer activity of HTF-1. It is rare to discover novel anti-cancer CG during the past couple of decades. We believe that our work will enrich the understanding of CGs; also, pave the way for natural product-based anti-cancer drug development.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-Cancer; Apoptosis; Cardiac glycoside; ERK and JNK pathways; Helleborus thibetanus Franch.; PI3K-Akt-mTOR pathway

Mesh:

Substances:

Year:  2018        PMID: 30245398     DOI: 10.1016/j.ejmech.2018.09.019

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

Review 1.  Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.

Authors:  Leilei Fu; Wenke Jin; Jiahui Zhang; Lingjuan Zhu; Jia Lu; Yongqi Zhen; Lan Zhang; Liang Ouyang; Bo Liu; Haiyang Yu
Journal:  Acta Pharm Sin B       Date:  2021-09-10       Impact factor: 11.413

2.  The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Authors:  Lei Zhang; Yidong Li; Qianchao Wang; Zhuo Chen; Xiaoyun Li; Zhuoxun Wu; Chaohua Hu; Dan Liao; Wei Zhang; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2020-01-17       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.